Half-year report · Q2
2689.TEDINET S100V7MJ
Period2024-07-01 → 2024-12-31
Filed2025-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥60.6bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥118.6bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥57.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | ¥808m | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥747m | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥824m | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.2bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥746m | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥816m | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥745m | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥648m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥486m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥648m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥486m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥46.8bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥43.2bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥43.4bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥35.3bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥31.9bn | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥11.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.4bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.7bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥800m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥146m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥889m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥673m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥347m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.0bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥109.44 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥251.68 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.01 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 24.6% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.4% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥880m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥880m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | −¥67m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥19,000 |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥105m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥57.3bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥56.5bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥816m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥715m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥2.8bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥2.8bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥64m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥55m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-07-01 → 2024-12-31 | ¥61.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-07-01 → 2024-12-31 | ¥60.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥880m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-07-01 → 2024-12-31 | ¥875m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥725m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥725m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥76m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥1.3bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥1.3bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥1m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥102m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥54.3bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥53.6bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥656m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥669m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥2.6bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥2.5bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥68m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥52m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-07-01 → 2023-12-31 | ¥58.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-07-01 → 2023-12-31 | ¥57.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥725m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-07-01 → 2023-12-31 | ¥823m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 522
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding allowances directly deducted from balances of assets (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |